Here are the S-1 registration statements from Traws Pharma, Inc. (TRAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. (TRAW) registered for resale by Roth Principal Investments, LLC up to 135,135,135 shares of common stock that Traws may elect to issue and sell to Roth under a purchase agreement. After Commencement and satisfaction of the agreement’s conditions, Traws may sell up to $50,000,000 in aggregate gross proceeds, but is not obligated to sell shares. Traws receives no proceeds from Roth’s resales.
Purchases are generally priced at 94.0% of VWAP, a 6.0% discount; block purchases require Roth’s prior written consent and are priced at 94.0% of the closing price. Issuances are subject to a 3,072,118-share Exchange Cap, unless stockholders approve more shares or the average purchase price meets the $0.3663 Base Price and continues to do so, and to a 4.99% beneficial ownership limit. The registered share count is approximately 879.3% of the 15,368,277 shares outstanding as of October 22, 2026. Actual sales depend on Traws’ decisions and the agreement’s conditions.